Overview

A Study of Anlotinib in Patients With Hepatocellular Carcinoma

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).
Phase:
Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd